MedTrace Logo

Study to Evaluate Surgical Excision Margins in Malignant Breast Lumpectomies With the PEAK PlasmaBlade

NCT00972010 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 21

Last updated 2019-07-12

No results posted yet for this study

Summary

The purpose of this research study is to find out more about distinguishing between cancerous and non-cancerous breast cancer cells at the edges of tumors. Using an FDA approved device to remove tumors, this device will be tested to see if it causes less tissue damage and therefore makes it easier to examine the tumor and make sure it is all excised. The tumors will be excised by standard surgical technique, and then the effects of the device on the removed tissues will be studied.

Conditions

Sponsors & Collaborators

  • Medtronic Surgical Technologies

    collaborator INDUSTRY

  • Sarah Blair, M.D.

    lead OTHER

Principal Investigators

  • Sarah L Blair, MD · University of California, San Diego

Eligibility

Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-07-31
Primary Completion
2010-07-31
Completion
2010-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00972010 on ClinicalTrials.gov